Security Industry News; Marco Hegyi, Seasoned Technology Executive, Named Visualant (OTCBB:VSUL) Chairman
SEATTLE - May 12, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that Marco Hegyi has been named Chairman of the Board of Directors of the Company.
Mr. Hegyi has served as an independent director at Visualant since 2008. He has been a principal with The Chasm Group since 2006, and serves as a strategic advisor to both public and private companies. Mr. Hegyi's passion is in helping companies expand their businesses with innovative technologies and collaborative partnerships. Over the course of his 30 years in the technology industry, he has worked at Yahoo!, Microsoft, and held executive roles in several other companies.
"We are very excited to have Marco Hegyi's greater participation in the leadership of the Company," said Ron Erickson, Visualant CEO. "Marco's significant experience in bringing new products to market is a tremendous asset for Visualant as we bring our Spectral Pattern Matching ("SPM") technology out of the laboratory and into the marketplace."
As Chairman, Mr. Hegyi will work with Visualant management and SPM inventors Dr. Tom Furness and Dr. Brian Schowengerdt, both of whom have recently joined the Company as consultants.
"Visualant's unique and patented SPM technology is transformative and provides a foundation for numerous applications," stated Hegyi. "In this expanded role, I will help align recent and future acquisitions to realize the potential of SPM technology and deliver solutions for our customer's security and authentication needs."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
Thursday, May 12, 2011
Nanotechnology Stocks; mPhase Technologies (OTC.BB:XDSL) Releases Photo of Smart Surface Technology
LITTLE FALLS, NJ - May 12, 2011 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB:XDSL) today released a photograph that shows its smart surface technology's dramatic ability to repel liquids. In the embedded photograph the viewer can see individual water droplets in a 3x4 array sitting on top of an mPhase created smart porous silicon membrane.
The smart porous silicon membrane can repel both aqueous and many non-aqueous liquids. In this example, individual droplets of water are sitting atop silicon material containing thousands of microscopic holes, which repel the liquid from passing through the pores of the membrane.
Under controlled conditions, the liquid can be made to pass through the pores of the membrane, such that the liquid can interact with materials or chemicals that are located below the surface of the membrane.
The photograph shows an example of how smart surfaces materials have been used to develop a miniature reserve battery that has a very long shelf life, and which can be electronically triggered to turn on under programmable control, and how this technology can potentially be expanded to other non battery applications, such as the delivery of drugs or smart filters.
mPhase will also be following up this photograph with a video segment that describes how the smart surface components can be assembled using semiconductor packaging methods, into a reserve battery containing lithium chemistry, that was developed under a recently funded government grant, as a power source used in computer memory backup.
"We are continuing to make significant strides in the development of our smart surfaces technology as is evidenced by this remarkable photograph," said Ron Durando, president and CEO of mPhase Technologies.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab on a chip analytic systems, self cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.
In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio. http://www.mpowertech.com
Forward Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company s products in the market; the Company s success in technology and product development; the Company s ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company s SEC filings, including the financial statements and related information contained in the Company s SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
mPhase Technologies, Inc. 973 256 3737
LITTLE FALLS, NJ - May 12, 2011 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB:XDSL) today released a photograph that shows its smart surface technology's dramatic ability to repel liquids. In the embedded photograph the viewer can see individual water droplets in a 3x4 array sitting on top of an mPhase created smart porous silicon membrane.
The smart porous silicon membrane can repel both aqueous and many non-aqueous liquids. In this example, individual droplets of water are sitting atop silicon material containing thousands of microscopic holes, which repel the liquid from passing through the pores of the membrane.
Under controlled conditions, the liquid can be made to pass through the pores of the membrane, such that the liquid can interact with materials or chemicals that are located below the surface of the membrane.
The photograph shows an example of how smart surfaces materials have been used to develop a miniature reserve battery that has a very long shelf life, and which can be electronically triggered to turn on under programmable control, and how this technology can potentially be expanded to other non battery applications, such as the delivery of drugs or smart filters.
mPhase will also be following up this photograph with a video segment that describes how the smart surface components can be assembled using semiconductor packaging methods, into a reserve battery containing lithium chemistry, that was developed under a recently funded government grant, as a power source used in computer memory backup.
"We are continuing to make significant strides in the development of our smart surfaces technology as is evidenced by this remarkable photograph," said Ron Durando, president and CEO of mPhase Technologies.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab on a chip analytic systems, self cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.
In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio. http://www.mpowertech.com
Forward Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company s products in the market; the Company s success in technology and product development; the Company s ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company s SEC filings, including the financial statements and related information contained in the Company s SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
mPhase Technologies, Inc. 973 256 3737
Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Gold and Mining Stocks; GOLD BULLION (TSX-V: GBB) DRILLS 80 METRES OF 1.36 GRAMS PER TONNE GOLD
Vancouver, British Columbia - May 12, 2011 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) ("Gold Bullion") is pleased to announce additional drill results from their Granada Property, located along the Cadillac trend in Northwestern Quebec, 5 km south of the city of Rouyn-Noranda. Gold Bullion has now completed 24,000m of the planned 50,000m Phase 3 drill campaign. The continually-expanding mineralized area remains open in all directions and at depth. Highlights of the most recent assay results include:
Hole GR-10-108 - 74.44 metres grading 1.06 grams per tonne
Including - 2.00 metres grading 16.75 grams per tonne
Hole GR-10-173 - 80.00 metres grading 1.36 grams per tonne
Including - 1.00 metres grading 89.83 grams per tonne
Hole GR-11-200 -- 106.00 metres grading 0.81 grams per tonne
Including -- 1.50 metres grading 42.90 grams per tonne
Mineralization of the above three holes is within 7 metres from surface vertical. Drilling at the Granada property continues with 2 drill rigs on 24 hours a day 7 days a week schedule. The present mineralized zone now covers an area of 1.2 kilometres along strike and is up to 0.5 kilometres wide. Drilling has begun in the area of the Aukeko target, about 2 km east from Hole GR-10-17. In this area, mineralization still shows an east-west trend, but any relationship with the mineralization of the Granada property still remains to be determined. The Company plans to test the extent of the mineralization to depth of 450 metres vertical.
Four holes (GR-10-147, GR-10-156, GR-11-232 and GR-11-238) did not intersect significant mineralization and are therefore not included in the above table.
Widths reported in the preceding table are drill widths; true widths are unknown at this time. Assays are uncut, length-weighted average values. Lost core within mineralized intersections were incorporated as blank intervals and assigned a 0.0 g/t grade in all length-weighted calculations.
Gold Bullion's NQ drill program and drill core sampling, including the quality assurance/quality control program, are supervised by GENIVAR, Gold Bullion's geological consultant. Core from the above holes was sent to ALS Chemex Labs in Val d'Or, Quebec, and Accurassay Laboratory in Timmins, Ontario, for analysis. Gold was assayed by fire assay with additional metallics analysis done on samples where visible gold was identified. Analytical accuracy and precision are monitored by the analysis of reagent blanks and reference materials at both labs. Quality control is further assured by the insertion of blind certified standard reference material and blanks into the sample stream at regular intervals by Gold Bullion and GENIVAR personnel in order to independently assess analytical accuracy.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
The scientific and technical information in this release was prepared under the supervision of Ms. Nicole Rioux, P. Geo., GENIVAR's senior geologist and a member of the Ordre des g�ologues du Qu�bec and a "qualified" person in accordance with National Instrument 43-101.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Vancouver, British Columbia - May 12, 2011 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) ("Gold Bullion") is pleased to announce additional drill results from their Granada Property, located along the Cadillac trend in Northwestern Quebec, 5 km south of the city of Rouyn-Noranda. Gold Bullion has now completed 24,000m of the planned 50,000m Phase 3 drill campaign. The continually-expanding mineralized area remains open in all directions and at depth. Highlights of the most recent assay results include:
Hole GR-10-108 - 74.44 metres grading 1.06 grams per tonne
Including - 2.00 metres grading 16.75 grams per tonne
Hole GR-10-173 - 80.00 metres grading 1.36 grams per tonne
Including - 1.00 metres grading 89.83 grams per tonne
Hole GR-11-200 -- 106.00 metres grading 0.81 grams per tonne
Including -- 1.50 metres grading 42.90 grams per tonne
Mineralization of the above three holes is within 7 metres from surface vertical. Drilling at the Granada property continues with 2 drill rigs on 24 hours a day 7 days a week schedule. The present mineralized zone now covers an area of 1.2 kilometres along strike and is up to 0.5 kilometres wide. Drilling has begun in the area of the Aukeko target, about 2 km east from Hole GR-10-17. In this area, mineralization still shows an east-west trend, but any relationship with the mineralization of the Granada property still remains to be determined. The Company plans to test the extent of the mineralization to depth of 450 metres vertical.
Four holes (GR-10-147, GR-10-156, GR-11-232 and GR-11-238) did not intersect significant mineralization and are therefore not included in the above table.Widths reported in the preceding table are drill widths; true widths are unknown at this time. Assays are uncut, length-weighted average values. Lost core within mineralized intersections were incorporated as blank intervals and assigned a 0.0 g/t grade in all length-weighted calculations.
Gold Bullion's NQ drill program and drill core sampling, including the quality assurance/quality control program, are supervised by GENIVAR, Gold Bullion's geological consultant. Core from the above holes was sent to ALS Chemex Labs in Val d'Or, Quebec, and Accurassay Laboratory in Timmins, Ontario, for analysis. Gold was assayed by fire assay with additional metallics analysis done on samples where visible gold was identified. Analytical accuracy and precision are monitored by the analysis of reagent blanks and reference materials at both labs. Quality control is further assured by the insertion of blind certified standard reference material and blanks into the sample stream at regular intervals by Gold Bullion and GENIVAR personnel in order to independently assess analytical accuracy.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
The scientific and technical information in this release was prepared under the supervision of Ms. Nicole Rioux, P. Geo., GENIVAR's senior geologist and a member of the Ordre des g�ologues du Qu�bec and a "qualified" person in accordance with National Instrument 43-101.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Wednesday, May 11, 2011
Oil and Gas News Alert; American Petro-Hunter (OTCBB: AAPH) Announces the Addition of Two New Wells on Pump
SCOTTSDALE, AZ � May 11, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is very pleased to announce today that the Company has brought both of its newest wells on pump at two separate North Oklahoma Project locations.
Pump equipment has been successfully installed at the NOS122 well site and has begun a test phase. Prior to installation, the well "free-flowed" oil to the test tank. Previous swab tests resulted in high gravity oil of 100% oil cut with no water from 6 feet of pay. Initial test results look excellent and American Petro-Hunter is anticipating a strong producer.
The well will continue to be evaluated over a period of weeks in order to identify initial production rates and ultimately to determine stable production rates projected over time. The tank battery and full production facilities are under construction. The Company has a minimum of 3 additional offsets to the NOS122 for future development and site engineering has been designed to accommodate future production requirements.
The second location to go on pump this week was at the NOS227 well site. Following a "multi-stage surge frack," where multiple injections of liquefied frack sand "proppants" were forced under high pressure into the Mississippi pay zone, the stimulation process successfully fractured the limestone reservoir allowing for an anticipated increase in the flow of oil. In readiness for commercial production, the pumping unit, rods and tubing have already been installed at NOS227. Over the next 12-15 days the frack load will be pumped off allowing the oil to commence flowing freely.
American Petro-Hunter has a 50% interest in both wells and production from the NOS122 and NOS227 will be sold alongside output from the No. 1 and NOJ26 wells to Sunoco, the regional purchaser. The latest achievements will increase the Company's revenue advantage to 4 producing wells in Oklahoma and two in Kansas.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the UnitedStates
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
SCOTTSDALE, AZ � May 11, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is very pleased to announce today that the Company has brought both of its newest wells on pump at two separate North Oklahoma Project locations.
Pump equipment has been successfully installed at the NOS122 well site and has begun a test phase. Prior to installation, the well "free-flowed" oil to the test tank. Previous swab tests resulted in high gravity oil of 100% oil cut with no water from 6 feet of pay. Initial test results look excellent and American Petro-Hunter is anticipating a strong producer.
The well will continue to be evaluated over a period of weeks in order to identify initial production rates and ultimately to determine stable production rates projected over time. The tank battery and full production facilities are under construction. The Company has a minimum of 3 additional offsets to the NOS122 for future development and site engineering has been designed to accommodate future production requirements.
The second location to go on pump this week was at the NOS227 well site. Following a "multi-stage surge frack," where multiple injections of liquefied frack sand "proppants" were forced under high pressure into the Mississippi pay zone, the stimulation process successfully fractured the limestone reservoir allowing for an anticipated increase in the flow of oil. In readiness for commercial production, the pumping unit, rods and tubing have already been installed at NOS227. Over the next 12-15 days the frack load will be pumped off allowing the oil to commence flowing freely.
American Petro-Hunter has a 50% interest in both wells and production from the NOS122 and NOS227 will be sold alongside output from the No. 1 and NOJ26 wells to Sunoco, the regional purchaser. The latest achievements will increase the Company's revenue advantage to 4 producing wells in Oklahoma and two in Kansas.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Tuesday, May 10, 2011
Online Mining Conference, Follow the Money in Mining and Metals, Showcases Well - Known Mining and Gold Stocks as well as Newsletter Writers and Analysts
May 10, 2011 - www.Investorideas.com and www.SmallCapVoice.com, present this years online mining conference for investors following gold and mining stocks. Investors can register for this free online event to hear from management of well-known mining stocks as well as hear commentary from newsletter writers and industry analysts.
Mining company, Goldcorp (TSX: G, NYSE: GG)will present as the keynote mining stock at online mining conference, Follow the Money in Mining and Metals, May 25 th and 26. Presenting mining stocks also include; Currie Rose (TSX.V: CUI) (OTC: CUIRF), Strategic Resources (TSXV: UVR), Yale (TSX-V - YLL and Frankfurt – YAB, Running Fox (TSX-V: RUN) and Trueclaim Exploration Inc. (TSX-V: TRM).
Resource speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
The online conference is free to investors with login registration. The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25 th starting at 9:00 a.m. EST. It will be archived for three months and available with login. The conference pages will be featured for investors at both Investorideas.com and SmallCapvoice.com.
Learn More about the Mining Conference
http://www.investorideas.com/MSS/Conference.asp
Free Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Mining Stocks:
Goldcorp (TSX: G, NYSE: GG)
Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas. Our strong project pipeline is positioned to drive long-term, sustainable growth. A Canadian company headquartered in Vancouver, British Columbia, Goldcorp employs more than 11,500 people worldwide. Goldcorp is committed to responsible mining practices and is well-positioned to deliver sustained, industry leading growth and performance. We endeavor to deliver sustainable prosperity for our shareholders, employees, business partners and the communities in which we operate.
Contact
Jeff Wilhoit
VP, Investor Relations
(604) 696-3074
info@goldcorp.com
www.goldcorp.com
Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM)
Trueclaim Exploration Inc. is a mineral exploration company. Trueclaim is engaged in the acquisition and development of precious and base metals properties in strategically located areas, currently within Ontario and Arizona.The Company's current principal project is the former Scadding Gold Mine near Sudbury, Ontario. The Scadding claims are part of approximately 45,000 acres the Company has assembled in this area.
Contact
Jim Elbert
jelbert@trueclaim.ca
www.trueclaimexploration.com
Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q)
Running Fox is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
Contact
Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Yale Resources Yale Resources Ltd. is an exploration and development company building value utilizing the Project Generator business model. With its Mexican operations based out of Hermosillo, Sonora, Yale is utilizing its extensive Mexican network to identify, acquire and advance projects of merit. Yale's partners are scheduled to spend greater than $1,000,000 on exploration on the Company's properties over the next 12 months.
Contact
Ian Foreman
info@yaleresources.com
www.yaleresources.com
Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF)
Currie Rose Resources Inc. is a gold exploration company listed on the Toronto Venture Exchange under the symbol CUI-V, Frankfurt Exchange CDV, and U.S. OTC Market symbol CUIRF. The main focus is the Company's gold exploration projects in The Lake Victoria Gold Fields in Tanzania
IR contact
Harold Smith
harold@currierose.com
www.currierose.com
Strategic Resources (TSXV: UVR)
Strategic Resources is a Canadian based junior exploration company with uranium/vanadium exploration projects in Catron County, New Mexico, Rare Earth exploration projects in Lincoln County and Socorro County, New Mexico and a Lithium project in Malheur County, Oregon.
www.strategicresourcesinc.ca
IR Contact
Malcolm Bucholtz
Supercyclereport@gmail.comSupercyclereport@gmail.com
Media sponsors include the Streetwise Reports / Gold Report, mining investor sites Mine Snooper www.minesnooper.com , International Mining Research Inc (www.internationalminingresearch.com ) and the investor research magazine, the Opportunist.
About www.InvestorIdeas.com: Investor Ideas that Can Change the World
Investor Ideas is a global financial media online destination specialized in sector investing content including mining and energystocks .
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and onlineadvertising . www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: YLL is also a featured showcase stock on Investorideas.com
Learn more: http://www.investorideas.com/About/News/Clientspecifics.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source - Investorideas.com, SmallCapVoice.com
May 10, 2011 - www.Investorideas.com and www.SmallCapVoice.com, present this years online mining conference for investors following gold and mining stocks. Investors can register for this free online event to hear from management of well-known mining stocks as well as hear commentary from newsletter writers and industry analysts.
Mining company, Goldcorp (TSX: G, NYSE: GG)will present as the keynote mining stock at online mining conference, Follow the Money in Mining and Metals, May 25 th and 26. Presenting mining stocks also include; Currie Rose (TSX.V: CUI) (OTC: CUIRF), Strategic Resources (TSXV: UVR), Yale (TSX-V - YLL and Frankfurt – YAB, Running Fox (TSX-V: RUN) and Trueclaim Exploration Inc. (TSX-V: TRM).
Resource speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
The online conference is free to investors with login registration. The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25 th starting at 9:00 a.m. EST. It will be archived for three months and available with login. The conference pages will be featured for investors at both Investorideas.com and SmallCapvoice.com.
Learn More about the Mining Conference
http://www.investorideas.com/MSS/Conference.asp
Free Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Mining Stocks:
Goldcorp (TSX: G, NYSE: GG)
Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas. Our strong project pipeline is positioned to drive long-term, sustainable growth. A Canadian company headquartered in Vancouver, British Columbia, Goldcorp employs more than 11,500 people worldwide. Goldcorp is committed to responsible mining practices and is well-positioned to deliver sustained, industry leading growth and performance. We endeavor to deliver sustainable prosperity for our shareholders, employees, business partners and the communities in which we operate.
Contact
Jeff Wilhoit
VP, Investor Relations
(604) 696-3074
info@goldcorp.com
www.goldcorp.com
Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM)
Trueclaim Exploration Inc. is a mineral exploration company. Trueclaim is engaged in the acquisition and development of precious and base metals properties in strategically located areas, currently within Ontario and Arizona.The Company's current principal project is the former Scadding Gold Mine near Sudbury, Ontario. The Scadding claims are part of approximately 45,000 acres the Company has assembled in this area.
Contact
Jim Elbert
jelbert@trueclaim.ca
www.trueclaimexploration.com
Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q)
Running Fox is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
Contact
Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Yale Resources Yale Resources Ltd. is an exploration and development company building value utilizing the Project Generator business model. With its Mexican operations based out of Hermosillo, Sonora, Yale is utilizing its extensive Mexican network to identify, acquire and advance projects of merit. Yale's partners are scheduled to spend greater than $1,000,000 on exploration on the Company's properties over the next 12 months.
Contact
Ian Foreman
info@yaleresources.com
www.yaleresources.com
Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF)
Currie Rose Resources Inc. is a gold exploration company listed on the Toronto Venture Exchange under the symbol CUI-V, Frankfurt Exchange CDV, and U.S. OTC Market symbol CUIRF. The main focus is the Company's gold exploration projects in The Lake Victoria Gold Fields in Tanzania
IR contact
Harold Smith
harold@currierose.com
www.currierose.com
Strategic Resources (TSXV: UVR)
Strategic Resources is a Canadian based junior exploration company with uranium/vanadium exploration projects in Catron County, New Mexico, Rare Earth exploration projects in Lincoln County and Socorro County, New Mexico and a Lithium project in Malheur County, Oregon.
www.strategicresourcesinc.ca
IR Contact
Malcolm Bucholtz
Supercyclereport@gmail.comSupercyclereport@gmail.com
Media sponsors include the Streetwise Reports / Gold Report, mining investor sites Mine Snooper www.minesnooper.com , International Mining Research Inc (www.internationalminingresearch.com ) and the investor research magazine, the Opportunist.
About www.InvestorIdeas.com: Investor Ideas that Can Change the World
Investor Ideas is a global financial media online destination specialized in sector investing content including mining and energy
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online
Disclosure: YLL is also a featured showcase stock on Investorideas.com
Learn more: http://www.investorideas.com/About/News/Clientspecifics.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source - Investorideas.com, SmallCapVoice.com
Security Industry News; Visualant (OTCBB:VSUL) Retains Dr. Brian Schowengerdt, Co-Inventor of Spectral Pattern Matching Technology
SEATTLE - May 10, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that Dr. Brian Schowengerdt, a co-inventor of Visualant's Spectral Pattern Matching (SPM) technology will consult with the Company.
Dr. Schowengerdt's work focuses on the intersection of the fields of photonics and biological sensory systems. He has developed novel 3D capture and display technologies using scanned light while at the University of Washington's Human Photonics Laboratory, the Department of Mechanical Engineering, and the Human Interface Technology Laboratory. In addition to giving numerous invited talks at conferences such as the Optical Society of America, Frontiers in Optics, and Optics and Photonics Japan, he has authored a wide range of articles and patents on optical and photonic systems. Dr. Schowengerdt is the program chair for 3D technology and chair of the Display Systems Committee of the Society for Information Display, and sits on the editorial board of multiple academic journals.
"The Visualant team is very pleased to have the active involvement of Dr. Brian Schowengerdt. He has been instrumental in the creation and development of the Visualant technology," said Ron Erickson, Company CEO. "We look forward to having Brian's capable assistance as we expand the reach and applications of the SPM technology and grow the Company to the next level."
"As a co-creator of the Visualant Spectral Pattern Matching technology I have a special commitment to its broad use in the marketplace as an authentication and diagnostic tool," stated Dr. Schowengerdt. "I look forward to assisting the Company as it exploits the many opportunities before it."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
SEATTLE - May 10, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that Dr. Brian Schowengerdt, a co-inventor of Visualant's Spectral Pattern Matching (SPM) technology will consult with the Company.
Dr. Schowengerdt's work focuses on the intersection of the fields of photonics and biological sensory systems. He has developed novel 3D capture and display technologies using scanned light while at the University of Washington's Human Photonics Laboratory, the Department of Mechanical Engineering, and the Human Interface Technology Laboratory. In addition to giving numerous invited talks at conferences such as the Optical Society of America, Frontiers in Optics, and Optics and Photonics Japan, he has authored a wide range of articles and patents on optical and photonic systems. Dr. Schowengerdt is the program chair for 3D technology and chair of the Display Systems Committee of the Society for Information Display, and sits on the editorial board of multiple academic journals.
"The Visualant team is very pleased to have the active involvement of Dr. Brian Schowengerdt. He has been instrumental in the creation and development of the Visualant technology," said Ron Erickson, Company CEO. "We look forward to having Brian's capable assistance as we expand the reach and applications of the SPM technology and grow the Company to the next level."
"As a co-creator of the Visualant Spectral Pattern Matching technology I have a special commitment to its broad use in the marketplace as an authentication and diagnostic tool," stated Dr. Schowengerdt. "I look forward to assisting the Company as it exploits the many opportunities before it."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclosure and Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs.
(1500 per month and $five thousand per month in restricted 144 shares)
Biotech and Pharma Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request for Hemopurifier® Investigational Device Exemption (IDE)
SAN DIEGO � May 10, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) reports it has submitted a request to the U.S. Food and Drug Administration (FDA) for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier® in the United States. Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.
Aethlon management will present FDA officials with new clinical data that supports the safety of the Hemopurifier® and demonstrates the capability of the medical device to reduce viral load in individuals infected with the hepatitis C virus (HCV). Based on the data to be presented, Aethlon will request permission to expand the target treatment indications of the Hemopurifier® to include HCV in the U.S. At present, the treatment indication underlying the Aethlon IDE is solely directed toward the use of the Hemopurifier® as a countermeasure against bioterror and pandemic threats.
"Since submitting our IDE, we have expanded our collection of human safety data, which has also provided insight that our Hemopurifier® can have a substantial effect in reducing viral load in HCV-infected patients even in the absence of antiviral drugs," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "These results combined with the emergence of a remarkable clinical validation for therapeutic filtration in HCV care provide a compelling basis for an FDA meeting to discuss and advance a potential clinical strategy to treat HCV-infected individuals in the United States."
The meeting with the FDA will provide a collaborative opportunity for Aethlon management to interact directly with Agency officials and to obtain guidance and input on advancing both its HCV and Medical Countermeasure indications in the U.S. Aethlon anticipates a meeting with FDA officials will likely occur in mid-summer.
The Company believes a significant and enduring opportunity exists for the Hemopurifier® as an adjunct to improve the benefit of current, forthcoming and future iterations of standard-of-care drug therapy (SOC) by accelerating viral load depletion in the first few days of HCV-SOC. The clinical validation for therapeutic filtration of HCV has been established by the VRAD system developed and marketed by Asahi Kasei Kuraray Medical in Japan. The early administration of VRAD in combination with HCV-SOC achieved 71.4% sustained virologic response rates (SVR) in HCV patients who previously failed HCV-SOC. These results were achieved through a once daily administration of VRAD for three consecutive days at the outset of SOC therapy. The average viral load reduction during each treatment period, which averaged 3 1/4 hours in duration, was 26.1%. In comparison, the Aethlon Hemopurifier® has demonstrated average viral load reductions of 64% during similar treatment timeframes in the absence of any drug therapy benefit. Aethlon is now actively advancing an adjunct study to demonstrate the ability of the Hemopurifier® to accelerate early viral load depletion in patients who initiate HCV-SOC. The study is being conducted at the Medanta Medicity Institute in Delhi, India.
The Hemopurifier® is also uniquely suited to treat HCV-infected End-stage renal disease (ESRD) patients, whose condition limits their ability to be treated with HCV-SOC. The incidence of HCV infection in ESRD patients is approximately 100-1000 times higher than that in the general population. Recent studies have clearly shown that HCV-infected ESRD patients on maintenance dialysis are at increased risk of liver-related mortality. A significant proportion develops chronic hepatitis, cirrhosis, and even hepatocellular carcinoma. Overall, chronic HCV patients on hemodialysis bear an increased risk of liver-related morbidity and mortality, either during dialysis or after renal transplantation. Interferon (IFN) therapy is modestly effective for the treatment of HCV infection in ESRD patients but is not recommended after renal transplantation due to the risk of acute graft rejection. Ribavirin is considered contraindicated for the treatment of ESRD patients with chronic hepatitis C because of the risk of life-threatening hemolytic anemia. A major advantage in treating HCV-infected ESRD patients with the Hemopurifier® is that the device adds no drug toxicity or interaction concerns and can be included in series with a patient's dialysis cartridge, thus adding no treatment burden beyond the patient's pre-established dialysis treatment schedule.
Aethlon further disclosed that it will begin discussions with the FDA on the regulatory requirements to obtain an Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats that emerge naturally or are released by man as an agent of bioterrorism. The Project BioShield Act of 2004 permits the FDA Commissioner to authorize the use of an unapproved medical product during a declared emergency involving a heightened risk of attack on the public or U.S. military forces, or a significant potential to affect national security. The EUA authority allows the FDA Commissioner to strengthen the public health protections against biological, chemical, radiological and nuclear agents that may be used to attack the American people or the U.S. armed forces. The FDA Commissioner may allow medical countermeasures to be used in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by such agents, when there are no adequate, approved and available alternatives.
Aethlon believes the Hemopurifier®, which is the sole antiviral strategy to address drug and vaccine resistant viral pathogens, is well positioned to meet the U.S. government's urgent need for innovative new medical countermeasures that can be deployed during national health emergencies.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO � May 10, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) reports it has submitted a request to the U.S. Food and Drug Administration (FDA) for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier® in the United States. Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.
Aethlon management will present FDA officials with new clinical data that supports the safety of the Hemopurifier® and demonstrates the capability of the medical device to reduce viral load in individuals infected with the hepatitis C virus (HCV). Based on the data to be presented, Aethlon will request permission to expand the target treatment indications of the Hemopurifier® to include HCV in the U.S. At present, the treatment indication underlying the Aethlon IDE is solely directed toward the use of the Hemopurifier® as a countermeasure against bioterror and pandemic threats.
"Since submitting our IDE, we have expanded our collection of human safety data, which has also provided insight that our Hemopurifier® can have a substantial effect in reducing viral load in HCV-infected patients even in the absence of antiviral drugs," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "These results combined with the emergence of a remarkable clinical validation for therapeutic filtration in HCV care provide a compelling basis for an FDA meeting to discuss and advance a potential clinical strategy to treat HCV-infected individuals in the United States."
The meeting with the FDA will provide a collaborative opportunity for Aethlon management to interact directly with Agency officials and to obtain guidance and input on advancing both its HCV and Medical Countermeasure indications in the U.S. Aethlon anticipates a meeting with FDA officials will likely occur in mid-summer.
The Company believes a significant and enduring opportunity exists for the Hemopurifier® as an adjunct to improve the benefit of current, forthcoming and future iterations of standard-of-care drug therapy (SOC) by accelerating viral load depletion in the first few days of HCV-SOC. The clinical validation for therapeutic filtration of HCV has been established by the VRAD system developed and marketed by Asahi Kasei Kuraray Medical in Japan. The early administration of VRAD in combination with HCV-SOC achieved 71.4% sustained virologic response rates (SVR) in HCV patients who previously failed HCV-SOC. These results were achieved through a once daily administration of VRAD for three consecutive days at the outset of SOC therapy. The average viral load reduction during each treatment period, which averaged 3 1/4 hours in duration, was 26.1%. In comparison, the Aethlon Hemopurifier® has demonstrated average viral load reductions of 64% during similar treatment timeframes in the absence of any drug therapy benefit. Aethlon is now actively advancing an adjunct study to demonstrate the ability of the Hemopurifier® to accelerate early viral load depletion in patients who initiate HCV-SOC. The study is being conducted at the Medanta Medicity Institute in Delhi, India.
The Hemopurifier® is also uniquely suited to treat HCV-infected End-stage renal disease (ESRD) patients, whose condition limits their ability to be treated with HCV-SOC. The incidence of HCV infection in ESRD patients is approximately 100-1000 times higher than that in the general population. Recent studies have clearly shown that HCV-infected ESRD patients on maintenance dialysis are at increased risk of liver-related mortality. A significant proportion develops chronic hepatitis, cirrhosis, and even hepatocellular carcinoma. Overall, chronic HCV patients on hemodialysis bear an increased risk of liver-related morbidity and mortality, either during dialysis or after renal transplantation. Interferon (IFN) therapy is modestly effective for the treatment of HCV infection in ESRD patients but is not recommended after renal transplantation due to the risk of acute graft rejection. Ribavirin is considered contraindicated for the treatment of ESRD patients with chronic hepatitis C because of the risk of life-threatening hemolytic anemia. A major advantage in treating HCV-infected ESRD patients with the Hemopurifier® is that the device adds no drug toxicity or interaction concerns and can be included in series with a patient's dialysis cartridge, thus adding no treatment burden beyond the patient's pre-established dialysis treatment schedule.
Aethlon further disclosed that it will begin discussions with the FDA on the regulatory requirements to obtain an Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats that emerge naturally or are released by man as an agent of bioterrorism. The Project BioShield Act of 2004 permits the FDA Commissioner to authorize the use of an unapproved medical product during a declared emergency involving a heightened risk of attack on the public or U.S. military forces, or a significant potential to affect national security. The EUA authority allows the FDA Commissioner to strengthen the public health protections against biological, chemical, radiological and nuclear agents that may be used to attack the American people or the U.S. armed forces. The FDA Commissioner may allow medical countermeasures to be used in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by such agents, when there are no adequate, approved and available alternatives.
Aethlon believes the Hemopurifier®, which is the sole antiviral strategy to address drug and vaccine resistant viral pathogens, is well positioned to meet the U.S. government's urgent need for innovative new medical countermeasures that can be deployed during national health emergencies.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Green Car Stocks; EVCARCO, Inc. (OTCBB: EVCA) Signs $10 Million Funding Commitment With Auctus Private Equity Fund, LLC
FT. WORTH, TX � May 10, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (OTCQB:EVCA) announced today that it has signed a $10 Million drawdown equity financing agreement with Boston based Auctus Private Equity Fund, LLC ("Auctus").
Mack Sanders, CEO of EVCARCO, stated, "We are pleased to have signed this funding agreement with Auctus, which provides the Company with future flexibility and will help us with dealership acquisitions, operations and general corporate use."
Nickolay Frolov, CFO of EVCARCO, remarked, "The Auctus Agreement requires the Company to file for fewer shares and should have a gradual effect on our share structure due to the 36 month term. The Company is also looking at several smaller debt financing packages from other firms and financiers to help leverage the Company's need for funding and growth."
There are no upper limits to the price Auctus may pay to purchase EVCARCO's common stock and the purchase price of the shares related to the $10 Million of future funding will be based on 93% of the lowest trade (closing) price during the pricing period as outlined in the Agreement. The Company will control the timing and amount of any sales of shares to Auctus. There are no financial or business covenants, restrictions on future funding, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. The Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty.
A more detailed description of the Agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC.
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
FT. WORTH, TX � May 10, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (OTCQB:EVCA) announced today that it has signed a $10 Million drawdown equity financing agreement with Boston based Auctus Private Equity Fund, LLC ("Auctus").
Mack Sanders, CEO of EVCARCO, stated, "We are pleased to have signed this funding agreement with Auctus, which provides the Company with future flexibility and will help us with dealership acquisitions, operations and general corporate use."
Nickolay Frolov, CFO of EVCARCO, remarked, "The Auctus Agreement requires the Company to file for fewer shares and should have a gradual effect on our share structure due to the 36 month term. The Company is also looking at several smaller debt financing packages from other firms and financiers to help leverage the Company's need for funding and growth."
There are no upper limits to the price Auctus may pay to purchase EVCARCO's common stock and the purchase price of the shares related to the $10 Million of future funding will be based on 93% of the lowest trade (closing) price during the pricing period as outlined in the Agreement. The Company will control the timing and amount of any sales of shares to Auctus. There are no financial or business covenants, restrictions on future funding, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. The Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty.
A more detailed description of the Agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC.
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Rare Earth Mining Stocks; Cavan (TSX.V-CVN), Enters LOI for Acquisition of Quebec Rare Earth Project, Proposed $1.5 Million and $1.0 Million Flow-through Financing
Vancouver, British Columbia, CANADA - May 10, 2011 (Investorideas.com Mining stocks newswire) - Cavan Ventures Inc. (TSX.V-CVN), (http://www.cavanventures.com) (the "Company") is pleased to announce it has entered into a non-binding Letter Of Intent ("LOI") with Investissements Horizon Inc. ("IHI") of Quebec, to acquire from IHI up to one hundred percent (100%) interest in the Pythonga Lake Rare Earth project ("Pythonga") in the Maniwaki region in the province of Quebec. The 8.3km2 Pythonga lake project is comprised of 14 mining claims and is situated 180km northwest of Montreal in the Maniwaki region. The Maniwaki region has recently seen a great deal of exploration activity associated with rare earth elements discoveries.
Cavan will immediately commence a due diligence review of the project. Upon successful completion of the due diligence review the parties will proceed to enter into and execute a definitive agreement with respect to the acquisition by Cavan of up to 100 % interest in the Pythonga project. Cavan will issue a news release to provide an update to its shareholders in connection with the execution of the definitive agreement. The proposed terms to purchase a seventy percent (70%) interest of the property is cash payment of $50,000 and 2,000,000 common shares of Company stock to IHI. Cavan also agrees to spend $500,000 for an exploration program on the property over 2 years. Cavan can issue an additional 3,000,000 shares of Company stock to purchase the remaining thirty percent (30%) of the Pythonga project for a total one hundred percent (100%) interest.
Completion of the transaction is subject to a number of conditions, including TSX Venture Exchange acceptance and, if required, shareholder approval. There can be no assurance that the transaction will be completed as proposed or at all.
Cavan intends to complete a non-brokered private placement of up to 7.5 million units to subscribers to residents in Canada and certain offshore jurisdictions at a price of 20 cents ($0.20) per unit for gross proceeds of up to $1,500,000. Each unit will comprise one common share of the company and one-half of one non-transferable warrant of the company. Each whole warrant will entitle the holder thereof to acquire one common share of the company at an exercise price of 25 cents ($0.25) per common share for a period of 18 months after the closing date of the private placement.
Cavan also intends to complete a non-brokered private placement of up to 4 million flow-through units at a price of 25 cents ($0.25) per unit for gross proceeds of up to $1,000,000. Each unit will comprise one flow-through common share of the company and one-half of one non-transferable warrant of the company. Each whole warrant will entitle the holder thereof to acquire one non flow-though common share of the company at an exercise price of 30 cents ($0.30) per common share for a period of 18 months after the closing date of the private placement.
In connection with the private placement, The Company may pay a finder's fee, payable in cash or shares, to certain arm's-length parties in an amount equal to 8 per cent of the total gross proceeds raised under the private placement from subscribers introduced to the company by such parties.
The securities issued under the private placement will be subject to a statutory hold period which will expire four months and one day from the date of the closing of the private placement. The private placement is subject to acceptance by the TSX Venture Exchange and other customary conditions for a transaction of this nature. The proceeds of the private placement will be used for mineral exploration activities of the company and for general working capital purposes.
On behalf of the Board of Directors:
"Andrew Mah"
Andrew Mah, President & Director
(604)783 5328 (cell) or (604)288 2756
andrew.mah@cavanventures.com
or
Patrick Brandreth
Director, Corporate communication: (604) 808 3527
patrick@cavanventures.com
For further information please visit our website at www.cavanventures.com
This news release contains certain forward-looking statements that reflect the current views and/or expectations of Cavan with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Vancouver, British Columbia, CANADA - May 10, 2011 (Investorideas.com Mining stocks newswire) - Cavan Ventures Inc. (TSX.V-CVN), (http://www.cavanventures.com) (the "Company") is pleased to announce it has entered into a non-binding Letter Of Intent ("LOI") with Investissements Horizon Inc. ("IHI") of Quebec, to acquire from IHI up to one hundred percent (100%) interest in the Pythonga Lake Rare Earth project ("Pythonga") in the Maniwaki region in the province of Quebec. The 8.3km2 Pythonga lake project is comprised of 14 mining claims and is situated 180km northwest of Montreal in the Maniwaki region. The Maniwaki region has recently seen a great deal of exploration activity associated with rare earth elements discoveries.
Cavan will immediately commence a due diligence review of the project. Upon successful completion of the due diligence review the parties will proceed to enter into and execute a definitive agreement with respect to the acquisition by Cavan of up to 100 % interest in the Pythonga project. Cavan will issue a news release to provide an update to its shareholders in connection with the execution of the definitive agreement. The proposed terms to purchase a seventy percent (70%) interest of the property is cash payment of $50,000 and 2,000,000 common shares of Company stock to IHI. Cavan also agrees to spend $500,000 for an exploration program on the property over 2 years. Cavan can issue an additional 3,000,000 shares of Company stock to purchase the remaining thirty percent (30%) of the Pythonga project for a total one hundred percent (100%) interest.
Completion of the transaction is subject to a number of conditions, including TSX Venture Exchange acceptance and, if required, shareholder approval. There can be no assurance that the transaction will be completed as proposed or at all.
Cavan intends to complete a non-brokered private placement of up to 7.5 million units to subscribers to residents in Canada and certain offshore jurisdictions at a price of 20 cents ($0.20) per unit for gross proceeds of up to $1,500,000. Each unit will comprise one common share of the company and one-half of one non-transferable warrant of the company. Each whole warrant will entitle the holder thereof to acquire one common share of the company at an exercise price of 25 cents ($0.25) per common share for a period of 18 months after the closing date of the private placement.
Cavan also intends to complete a non-brokered private placement of up to 4 million flow-through units at a price of 25 cents ($0.25) per unit for gross proceeds of up to $1,000,000. Each unit will comprise one flow-through common share of the company and one-half of one non-transferable warrant of the company. Each whole warrant will entitle the holder thereof to acquire one non flow-though common share of the company at an exercise price of 30 cents ($0.30) per common share for a period of 18 months after the closing date of the private placement.
In connection with the private placement, The Company may pay a finder's fee, payable in cash or shares, to certain arm's-length parties in an amount equal to 8 per cent of the total gross proceeds raised under the private placement from subscribers introduced to the company by such parties.
The securities issued under the private placement will be subject to a statutory hold period which will expire four months and one day from the date of the closing of the private placement. The private placement is subject to acceptance by the TSX Venture Exchange and other customary conditions for a transaction of this nature. The proceeds of the private placement will be used for mineral exploration activities of the company and for general working capital purposes.
On behalf of the Board of Directors:
"Andrew Mah"
Andrew Mah, President & Director
(604)783 5328 (cell) or (604)288 2756
andrew.mah@cavanventures.com
or
Patrick Brandreth
Director, Corporate communication: (604) 808 3527
patrick@cavanventures.com
For further information please visit our website at www.cavanventures.com
This news release contains certain forward-looking statements that reflect the current views and/or expectations of Cavan with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Oil and Gas Stocks News; American Petro-Hunter, Inc. (OTCBB: AAPH), Begins Multi-Stage Surge Frack at North Oklahoma Project
AUSTIN, Texas � May 10, 2011 (Investorideas.com energy newswire) - SmallCapVoice.com, Inc. announced today that a new audio interview featuring, American Petro-Hunter, Inc. (OTC.BB:AAPH) is now available. The interview can be heard http://smallcapvoice.com/blog/5-6-11-audio-interview-with-american-petro-hunter-otcbb-aaph
Cashing in on Oklahoma's oil and gas boom, American Petro-Hunter Inc. (OTCBB:AAPH.ob - News) has acquired a varied working interest in seven lease blocks over 3,400 acres in Northern Oklahoma. Currently, the Company has drilled, completed and put into production 2 vertical wells with a 3rd well of commercial viability coming online shortly in the Woodford Shale and Mississippi Limestone. This past week the company announced the commencement of a "multi-stage surge frack" regarded as the final event in the completion process at its NOS227 well in Northern Oklahoma. The Company announced goal is to become a 1000 BOE producer. For more information, please visit www.americanpetrohunterinc.com
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
SmallCapVoice is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and investor information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice and their services, please visit http://www.smallcapvoice.com/services.html.
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
Source: SmallCapVoice.com
AUSTIN, Texas � May 10, 2011 (Investorideas.com energy newswire) - SmallCapVoice.com, Inc. announced today that a new audio interview featuring, American Petro-Hunter, Inc. (OTC.BB:AAPH) is now available. The interview can be heard http://smallcapvoice.com/blog/5-6-11-audio-interview-with-american-petro-hunter-otcbb-aaph
Cashing in on Oklahoma's oil and gas boom, American Petro-Hunter Inc. (OTCBB:AAPH.ob - News) has acquired a varied working interest in seven lease blocks over 3,400 acres in Northern Oklahoma. Currently, the Company has drilled, completed and put into production 2 vertical wells with a 3rd well of commercial viability coming online shortly in the Woodford Shale and Mississippi Limestone. This past week the company announced the commencement of a "multi-stage surge frack" regarded as the final event in the completion process at its NOS227 well in Northern Oklahoma. The Company announced goal is to become a 1000 BOE producer. For more information, please visit www.americanpetrohunterinc.com
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
SmallCapVoice is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and investor information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice and their services, please visit http://www.smallcapvoice.com/services.html.
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
Source: SmallCapVoice.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports First Quarter Financial Results and Recent Developments
LINCOLNSHIRE, Ill. - May 10, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today reported on its financial results for the first quarter, cash balance as of March 31, 2011 and recent developments.
First Quarter 2011 Financial Results
BioSante's cash balance as of March 31, 2011 was approximately $51.3 million, compared to a cash balance of approximately $38.2 million on December 31, 2010.
BioSante incurred a net loss of approximately $17.3 million or $(0.20) per share for the quarter ended March 31, 2011, compared to a net loss of $10.5 million or $(0.19) per share for the same period in 2010. This expected increase in net loss was due primarily to the conduct of the three ongoing LibiGel® (testosterone gel) Phase III clinical studies to support submission of a new drug application (NDA) for U.S. Food and Drug Administration (FDA) approval.
Recent BioSante Developments
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
LINCOLNSHIRE, Ill. - May 10, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today reported on its financial results for the first quarter, cash balance as of March 31, 2011 and recent developments.
First Quarter 2011 Financial Results
BioSante's cash balance as of March 31, 2011 was approximately $51.3 million, compared to a cash balance of approximately $38.2 million on December 31, 2010.
BioSante incurred a net loss of approximately $17.3 million or $(0.20) per share for the quarter ended March 31, 2011, compared to a net loss of $10.5 million or $(0.19) per share for the same period in 2010. This expected increase in net loss was due primarily to the conduct of the three ongoing LibiGel® (testosterone gel) Phase III clinical studies to support submission of a new drug application (NDA) for U.S. Food and Drug Administration (FDA) approval.
Recent BioSante Developments
- LibiGel® Phase III Efficacy Trials Enrollment Completed: BioSante completed enrollment of subjects in its two pivotal Phase III LibiGel (testosterone gel) efficacy trials in the first quarter. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
- LibiGel Phase III Safety Study Continues: For the fifth time, unblinded safety data were reviewed by the independent Data Monitoring Committee (DMC) of the LibiGel Cardiovascular and Breast Cancer Safety Study. As per DMC recommendation, the LibiGel safety study continues, with no modifications.
- Bio-T-Gel™ New Drug Application (NDA) Filed by BioSante Licensee, Teva Pharmaceuticals: An NDA for Bio-T-Gel (testosterone gel) for the treatment of male hypogonadism, was accepted for filing by the FDA following submission by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
- Pancreas Cancer Vaccine Positive Clinical Results and Melanoma Orphan Drug Designation: BioSante reported positive Phase II clinical results for its Pancreas Cancer Vaccine. The vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent. In addition, the vaccine demonstrated a 35 percent increase in one year survival, from 63 percent to 85 percent. BioSante also received Orphan Drug designation from the FDA's Office of Orphan Products Development for its Melanoma Cancer Vaccine.
- Closed $25.1 million Registered Direct Financing: BioSante closed a registered direct offering in March 2011, bringing its March 31, 2011 cash balance to approximately $51.3 million. BioSante's management believes this cash balance will be sufficient to finance operations and LibiGel clinical development well into 2012, without the need for additional funds.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Monday, May 09, 2011
Biotech Stock News Alert; Q1 Publishing Research Featuring Verisante Technology, Inc. (TSX-V: VRS) (OTC: VRSEF)
May 9, 2011 - Investorideas.com newswire; The following biotech stock report is issued by Q1 Publishing Research covering Verisante Technology, Inc. (TSX-V: VRS) (PINK SHEETS: VRSEF).
Investorideas.com Newswire features third party research and equity reports from multiple research firms in the industry.
To view a profile on the Company as aired on BTV, click on the following link
http://www.youtube.com/verisante#p/u/2/PHugTxLXQGI
To view the Zacks Investment Research Initiation Report, click on the following link:
http://verisante.com/docs/verisante_zacks.pdf
To view media articles and stories on the Company, click on the following link:
http://verisante.com/news/media/
Jump on this Rapidly Unfolding Med-Tech Innovation Now
By Andrew Mickey, Q1 Publishing
We've only had this feeling a few times before.
It's the feeling we're onto something big - real big - at a very early state.
The same feeling we had about fertilizer stocks in July 2006. The same feeling about the Nintendo Wii when it exploded in Japan and its US launch was still months away. Or when Intuitive Surgical's robotic surgery technology was just making it into hospitals.
You know the feeling you're sitting on your next five- or 10-bagger, you understand it, you know it's big, and you're just waiting for everyone else to figure it out.
Frankly, it's a rare feeling. It's even rarer in a market like this where everything seems priced for perfection.
It's rare, but it's not impossible. Right now, we've got that feeling one small and fast-growing company is about to change a lucrative medical field for the better. And do it soon.
But we're not alone here. Some of the leading medical journals and magazines see the enormous potential we've spotted.
Biotechnology Focus magazine calls this development "ingenious."
The BC Medical Journal says, "Preliminary clinical results have so far demonstrated 100% efficacy."
Darrell Rigel, a professor of dermatology at NYU's Langone Medical Center, told MIT's Technology Review journal there's "a need" for innovations like this.
Despite the medical community's excitement, it still hasn't gone mainstream…yet.
Our window of opportunity to buy into Verisante Technology (TSX-V: VRS or OTCQX: VRSEF) will not be open forever.
Right now Verisante is a small $35 million company, just on the verge of leading medical technology revolution, has shown stellar preliminary clinical results, and based on market comparables is a ten-bagger-in-waiting.
In a few months, all that will be history and Verisante will be value much higher. Let's start at the beginning.
The Next Big Med-Tech Winner
If you're like me, you've learned (the hard and often expensive way) to become highly skeptical when it comes to new technologies.
They consistently over promise and under deliver.
Well, I think Verisante has under promised and is set to over deliver.
Verisante is aquickly emerging medical technology (med-tech) company which, despite its small size, is on the verge of doing something truly revolutionary.
The technology has been in development for 10 years. Its development has been led by some of the world's leading cancer researchers. It has received funding from leading cancer research organizations including the BC Cancer Society.
And, although it's technology has the potential to change almost every field of medicine, it's initially focused on a subsector of the medical field that's overdue for innovation.
Now with a recent $5 million capital infusion to take it to final commercialization, Verisante is poised to make it very big, very soon.
10 Years of Development About to Pay Off
Verisante is has entered the final approval stages for its proprietary cancer screening device.
On the surface, Verisante's Aura device is really simple. It detects cancerous cells by an advanced laser scanning system. And it does it with an astonishing rate of accuracy.
Think of a price scanner at the grocery store. It scans a bar code and tells you the price. Verisante's Aura concern detection device scans a skin lesion and tells you if it's cancerous. (For a complete explanation of how it works, follow this link to a recent feature on Canada's BTV)
Again, it really is a simple concept. But the science behind it is much more advanced than that.
Most importantly though, the Aura has shown the potential to revolutionize cancer detection and save a lot of lives and money in the process.
Verisante has targeted melanoma, one of the most feared and costly to treat cancers, for its initial launch.
Future Market Domination
The Aura device has shown remarkable accuracy and consistency in detecting melanoma at a very early stage (more details below).
Skin cancer is one of the most common forms of cancer. More than two million Americans are diagnosed with it each year. It will affect one in five US residents. And at least 40% of Americans can expect to get non-melanoma skin cancer before they turn 65.
Melanoma specifically one of the most deadly types of cancer. If detected in the Stage I it has an 85% survival rate. In Stage IV the survival rate falls to an ominous 15%.
Melanoma and skin cancer is costly too. It costs $1.5 billion a year to treat melanoma alone.
Despite the high costs of treatment and its deadly nature, there has been little advancement in detection.
For decades, dermatologists have relied on their eyes and patients to self-identify abnormal growth in moles and skin lesions. These crude methods successfully identify about one in three cases of melanoma.
Recently, however, the markets had high expectations that one of Verisante's competitors made a major breakthrough in melanoma detection. And investors were willing to pay top dollar merely speculating the technology worked effectively and consistently enough for regulatory approval.
Why Verisante is a True 10-Bagger
Knowing differences between the Verisante's and MELA Sciences (NASDAQ:MELA) - Verisante's closes competitor - devices reveals the true opportunity here.
MELA has been one of the most closely watched med-tech device stocks over the last year.
MELA's melanoma detection device, MelaFind, was in the final stages of regulatory approval heading into the end of 2010.
Investors were willing to risk getting in early because the upside potential was massive. If approved, MELA would be dominating a mult-billion dollar market virtually overnight.
MELA shares ran to more than $9 per share in anticipation of U.S. Food and Drug Administration (FDA) approval. At its peak, the total market value exceeded $200 million. Keep in mind, MelaFind is only aimed at melanoma and not the many other cancers Verisante's Aura has the potential to be used to detect. And it still was worth $200 million.
Then last November the FDA rejected MELA's device and its shares plummeted.
But here's the thing, MELA's device was rejected for a number of reasons that Verisante will not be affected by.
MELA was rejected because of its low degree of accuracy and large number of false positives.
In my opinion, MelaFind was basically not much more effective than what a dermatologist can determine just by looking at a suspicious mole.
The FDA requires a device to have a certain level of accuracy and consistency. MelaFind had neither.
Now MELA is going to need more studies and more capital to complete those studies. Yet it still has a market value almost three times higher than Verisante.
Key to Success: The Molecular Signature
The key difference between MELA's device and Verisante's is how they identify potentially cancerous cells.
MelaFind takes a picture of a mole or lesion. It then analyzes it against a database of images of confirmed melanoma cases. It uses a proprietary algorithm to compare shapes, sizes, and abnormalities of the lesions. This method didn't produce the accuracy or consistency required by the FDA.
Verisante's device works in a completely different way.
The Aura device analyzes what I call the "molecular signature" of the mole or lesion to determine whether it's likely cancerous or not.
The Aura uses Raman spectroscopy to detect the potential cancer at the molecular level. The studies conducted on the Aura device confirm how effective this process is.
In a six-year clinical trial conducted at the University of British Columbia's dermatology department and Vancouver General Hospital (which has 80,000 dermatoligical patients per year), the Aura device has detected melanoma with incredible accuracy and consistency.
Over a preliminary sample of 274 lesions, the Aura identified 45 melanoma occurrences. Thirty four of those occurrences identified by Aura were confirmed by a biopsy.
These preliminary results give melanoma a 100% accuracy rate and, as a testament to the reliability of the device, a 70% specificity.
These rates are critical part of the regulatory review process. The accuracy rate shows Aura works. The specificity rate shows Aura doesn't give too many "false positive" diagnoses. After all, you can't have a device that gives too many false positives. It would be worthless if it did.
This kind of accuracy and specificity is the critical difference for Verisante. And it shows how revolutionary this product is.
But it takes more than a better mousetrap to be successful. And Verisante has laid out a business model that has been exceptionally profitable for many of the leading companies in the world.
A Dermatologist's Perspective
The most impressive part of Verisante is its business model for commercializing the Aura device.
Once the Aura is approved, Verisante has planned a way to generate a profit by both selling its Aura devices and still earning an ongoing stream of revenue.
Verisante is using the "razor and blade model."
Do you think Gillette makes a lot of money selling a Mach 3 razor for $12? They do, but they make a lot more selling $4 razors month after month after month. Verisante is using the same strategy.
Let's take it from a dermatologist's perspective.
A skin doctor would be able to buy an Aura device and generate a lot of revenue from it. They would be able to charge anywhere from $100 to $500 for a cancer screening and do it for thousands of patients each year.
Many, I'm sure, would be able to pay at least $50,000 for a device that could generate between $100,000 to $1 million a year in revenue from it.
Verisante will likely be able to be able to build Aura devices for about $10,000. This will likely improve as demand increases and economies of scale are achieved, but let's take the more conservative $10,000 estimate. Verisante would be able to sell the device for between $30,000 and $60,000 to dermatologists.
That's a solid margin. The real money, however, comes from the continuous revenue it would receive. The "blades" part of the razor and blade model.
Each screening with the Aura device requires a new tip. The tip includes a lens and other proprietary features to prevent misdiagnosis. Verisante sells the specialized tips required for each use. The tips would likely cost dermatologists $10 each and significantly less to produce.
Verisante would be generating between $20,000 and $50,000 in gross profit per sale of each device. Then it would generate anywhere from $10,000 to $100,000 in additional revenues from the specialized tips from each device owner per year, every year.
Multiply those numbers out over a few hundred dermatologists (although there are thousands around the world) and you get some staggering numbers.
It's a massive opportunity which has the potential to make Verisante a $1 billion company as the Aura spreads across high-demand markets in Canada, Europe, and the United States.
On top of that, it's important to keep in mind that's just with melanoma. Verisante's technology has been proven to successfully identify many different types of cancers. Early trials have shown its effectiveness in identifying lung, cervical, and colon cancer.
Melanoma is just where Verisante's technology has had most of the research and testing geared towards. Once you add in potential opportunities in the other cancers, Verisante's potential is exponentially higher over the long run.
Nearing the Finish Line
Verisante seems to have it all. It's better, cheaper, and potentially very profitable. But the key with any investment in medical technology is completing the regulatory approval processes.
Verisante is aiming at completing the regularity approval process in a faster, less-costly way.
First, most of the expensive and time-consuming research is already completed. The Aura device has been in development for about 10 years. And it already has one six-year study completed.
Now Verisante is in the final stages of approval with Canadian medical authorities. Final approval is expected to be made by the end of 2011.
After that, Verisante has already started the European approval process. It expects to the "CE Mark" (the symbol of European approval) to be granted as early as the end of 2011.
If and when this is approved, Verisante has instant access to markets in the European Union, South Africa, and Australia.
Finally, with European and Canadian approval in hand, its' going to then move to the United States. It needs more studies for U.S. approval, but like many other drugs and medical devices, it's a lot more likely to get approval in the United States after Canada and Europe give the official thumbs up.
A Big Winner in the Making
Verisante Technology (TSX-V:VRS or OTCQX:VRSEF) is in position to have an exciting few months ahead as the story unfolds and even more great years beyond that.
It has all the elements of a giant med-tech success story.
It has superior, proven technology.
It has years of costly and time-consuming research behind it.
It's very near to final regulatory approval in Canada.
It has shown the potential to save a lot of lives too.
On top of all that, Verisante was recently able to attract an addition $5 million capital infusion in a market where med-tech and biotech aren't getting very much venture capital.
Perhaps most importantly, Verisante has huge growth potential. At a mere $35 market cap, the upside is tremendous. Remember, its closest competitor, MELAScience, had a market value of about $200 million just in anticipation it would be successful. And after it got rejected by the FDA, it still has a $90 million market value.
That's the kind of potential here where once the Aura is approved; Verisante is on its way to being worth $1 billion.
Head over to Verisante.com to see for yourself.
Andrew Mickey
Chief Investment Strategist, Q1 Publishing
Disclosure: The editor does not own shares and is not paid by any of the companies mentioned for distribution of this report. It is, however, an open recommendation in Q1 Publishing's President's List premium research service.
If you like ideas and research like this, the President's List is a premium investment research focused on the maximum risk-reward opportunities available anywhere in the world. You can learn more about a no-risk trial offer here. Legal Disclaimer : The information contained on this e-mail and in other Q1 Publishing communications is intended for general information purposes only. Q1 Publishing has not taken into account the specific investment objectives of any particular investor. You should always seek the counsel of a professional financial advisor before purchasing or selling stock. Directors, employees and outside contributors to Q1 Publishing may hold substantial positions in the recommended securities and may increase or decrease such positions without notice. We believe the sources of information to be reliable but Q1 Publishing does not guarantee the accuracy or completeness of the information provided on this website or in other Q1 communications, and expressly disclaims liability for any errors or omissions that may be contained in the information
Investorideas.com disclaimer and disclosure - the following news is a paid news release distribution (one thousand for 2 releases) Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
The published report by Q1 Publishing is the property of Q1 Publishing and is not the opinion of Investorideas.com
May 9, 2011 - Investorideas.com newswire; The following biotech stock report is issued by Q1 Publishing Research covering Verisante Technology, Inc. (TSX-V: VRS) (PINK SHEETS: VRSEF).
Investorideas.com Newswire features third party research and equity reports from multiple research firms in the industry.
To view a profile on the Company as aired on BTV, click on the following link
http://www.youtube.com/verisante#p/u/2/PHugTxLXQGI
To view the Zacks Investment Research Initiation Report, click on the following link:
http://verisante.com/docs/verisante_zacks.pdf
To view media articles and stories on the Company, click on the following link:
http://verisante.com/news/media/
Jump on this Rapidly Unfolding Med-Tech Innovation Now
By Andrew Mickey, Q1 Publishing
We've only had this feeling a few times before.
It's the feeling we're onto something big - real big - at a very early state.
The same feeling we had about fertilizer stocks in July 2006. The same feeling about the Nintendo Wii when it exploded in Japan and its US launch was still months away. Or when Intuitive Surgical's robotic surgery technology was just making it into hospitals.
You know the feeling you're sitting on your next five- or 10-bagger, you understand it, you know it's big, and you're just waiting for everyone else to figure it out.
Frankly, it's a rare feeling. It's even rarer in a market like this where everything seems priced for perfection.
It's rare, but it's not impossible. Right now, we've got that feeling one small and fast-growing company is about to change a lucrative medical field for the better. And do it soon.
But we're not alone here. Some of the leading medical journals and magazines see the enormous potential we've spotted.
Biotechnology Focus magazine calls this development "ingenious."
The BC Medical Journal says, "Preliminary clinical results have so far demonstrated 100% efficacy."
Darrell Rigel, a professor of dermatology at NYU's Langone Medical Center, told MIT's Technology Review journal there's "a need" for innovations like this.
Despite the medical community's excitement, it still hasn't gone mainstream…yet.
Our window of opportunity to buy into Verisante Technology (TSX-V: VRS or OTCQX: VRSEF) will not be open forever.
Right now Verisante is a small $35 million company, just on the verge of leading medical technology revolution, has shown stellar preliminary clinical results, and based on market comparables is a ten-bagger-in-waiting.
In a few months, all that will be history and Verisante will be value much higher. Let's start at the beginning.
The Next Big Med-Tech Winner
If you're like me, you've learned (the hard and often expensive way) to become highly skeptical when it comes to new technologies.
They consistently over promise and under deliver.
Well, I think Verisante has under promised and is set to over deliver.
Verisante is aquickly emerging medical technology (med-tech) company which, despite its small size, is on the verge of doing something truly revolutionary.
The technology has been in development for 10 years. Its development has been led by some of the world's leading cancer researchers. It has received funding from leading cancer research organizations including the BC Cancer Society.
And, although it's technology has the potential to change almost every field of medicine, it's initially focused on a subsector of the medical field that's overdue for innovation.
Now with a recent $5 million capital infusion to take it to final commercialization, Verisante is poised to make it very big, very soon.
10 Years of Development About to Pay Off
Verisante is has entered the final approval stages for its proprietary cancer screening device.
On the surface, Verisante's Aura device is really simple. It detects cancerous cells by an advanced laser scanning system. And it does it with an astonishing rate of accuracy.
Think of a price scanner at the grocery store. It scans a bar code and tells you the price. Verisante's Aura concern detection device scans a skin lesion and tells you if it's cancerous. (For a complete explanation of how it works, follow this link to a recent feature on Canada's BTV)
Again, it really is a simple concept. But the science behind it is much more advanced than that.
Most importantly though, the Aura has shown the potential to revolutionize cancer detection and save a lot of lives and money in the process.
Verisante has targeted melanoma, one of the most feared and costly to treat cancers, for its initial launch.
Future Market Domination
The Aura device has shown remarkable accuracy and consistency in detecting melanoma at a very early stage (more details below).
Skin cancer is one of the most common forms of cancer. More than two million Americans are diagnosed with it each year. It will affect one in five US residents. And at least 40% of Americans can expect to get non-melanoma skin cancer before they turn 65.
Melanoma specifically one of the most deadly types of cancer. If detected in the Stage I it has an 85% survival rate. In Stage IV the survival rate falls to an ominous 15%.
Melanoma and skin cancer is costly too. It costs $1.5 billion a year to treat melanoma alone.
Despite the high costs of treatment and its deadly nature, there has been little advancement in detection.
For decades, dermatologists have relied on their eyes and patients to self-identify abnormal growth in moles and skin lesions. These crude methods successfully identify about one in three cases of melanoma.
Recently, however, the markets had high expectations that one of Verisante's competitors made a major breakthrough in melanoma detection. And investors were willing to pay top dollar merely speculating the technology worked effectively and consistently enough for regulatory approval.
Why Verisante is a True 10-Bagger
Knowing differences between the Verisante's and MELA Sciences (NASDAQ:MELA) - Verisante's closes competitor - devices reveals the true opportunity here.
MELA has been one of the most closely watched med-tech device stocks over the last year.
MELA's melanoma detection device, MelaFind, was in the final stages of regulatory approval heading into the end of 2010.
Investors were willing to risk getting in early because the upside potential was massive. If approved, MELA would be dominating a mult-billion dollar market virtually overnight.
MELA shares ran to more than $9 per share in anticipation of U.S. Food and Drug Administration (FDA) approval. At its peak, the total market value exceeded $200 million. Keep in mind, MelaFind is only aimed at melanoma and not the many other cancers Verisante's Aura has the potential to be used to detect. And it still was worth $200 million.
Then last November the FDA rejected MELA's device and its shares plummeted.
But here's the thing, MELA's device was rejected for a number of reasons that Verisante will not be affected by.
MELA was rejected because of its low degree of accuracy and large number of false positives.
In my opinion, MelaFind was basically not much more effective than what a dermatologist can determine just by looking at a suspicious mole.
The FDA requires a device to have a certain level of accuracy and consistency. MelaFind had neither.
Now MELA is going to need more studies and more capital to complete those studies. Yet it still has a market value almost three times higher than Verisante.
Key to Success: The Molecular Signature
The key difference between MELA's device and Verisante's is how they identify potentially cancerous cells.
MelaFind takes a picture of a mole or lesion. It then analyzes it against a database of images of confirmed melanoma cases. It uses a proprietary algorithm to compare shapes, sizes, and abnormalities of the lesions. This method didn't produce the accuracy or consistency required by the FDA.
Verisante's device works in a completely different way.
The Aura device analyzes what I call the "molecular signature" of the mole or lesion to determine whether it's likely cancerous or not.
The Aura uses Raman spectroscopy to detect the potential cancer at the molecular level. The studies conducted on the Aura device confirm how effective this process is.
In a six-year clinical trial conducted at the University of British Columbia's dermatology department and Vancouver General Hospital (which has 80,000 dermatoligical patients per year), the Aura device has detected melanoma with incredible accuracy and consistency.
Over a preliminary sample of 274 lesions, the Aura identified 45 melanoma occurrences. Thirty four of those occurrences identified by Aura were confirmed by a biopsy.
These preliminary results give melanoma a 100% accuracy rate and, as a testament to the reliability of the device, a 70% specificity.
These rates are critical part of the regulatory review process. The accuracy rate shows Aura works. The specificity rate shows Aura doesn't give too many "false positive" diagnoses. After all, you can't have a device that gives too many false positives. It would be worthless if it did.
This kind of accuracy and specificity is the critical difference for Verisante. And it shows how revolutionary this product is.
But it takes more than a better mousetrap to be successful. And Verisante has laid out a business model that has been exceptionally profitable for many of the leading companies in the world.
A Dermatologist's Perspective
The most impressive part of Verisante is its business model for commercializing the Aura device.
Once the Aura is approved, Verisante has planned a way to generate a profit by both selling its Aura devices and still earning an ongoing stream of revenue.
Verisante is using the "razor and blade model."
Do you think Gillette makes a lot of money selling a Mach 3 razor for $12? They do, but they make a lot more selling $4 razors month after month after month. Verisante is using the same strategy.
Let's take it from a dermatologist's perspective.
A skin doctor would be able to buy an Aura device and generate a lot of revenue from it. They would be able to charge anywhere from $100 to $500 for a cancer screening and do it for thousands of patients each year.
Many, I'm sure, would be able to pay at least $50,000 for a device that could generate between $100,000 to $1 million a year in revenue from it.
Verisante will likely be able to be able to build Aura devices for about $10,000. This will likely improve as demand increases and economies of scale are achieved, but let's take the more conservative $10,000 estimate. Verisante would be able to sell the device for between $30,000 and $60,000 to dermatologists.
That's a solid margin. The real money, however, comes from the continuous revenue it would receive. The "blades" part of the razor and blade model.
Each screening with the Aura device requires a new tip. The tip includes a lens and other proprietary features to prevent misdiagnosis. Verisante sells the specialized tips required for each use. The tips would likely cost dermatologists $10 each and significantly less to produce.
Verisante would be generating between $20,000 and $50,000 in gross profit per sale of each device. Then it would generate anywhere from $10,000 to $100,000 in additional revenues from the specialized tips from each device owner per year, every year.
Multiply those numbers out over a few hundred dermatologists (although there are thousands around the world) and you get some staggering numbers.
It's a massive opportunity which has the potential to make Verisante a $1 billion company as the Aura spreads across high-demand markets in Canada, Europe, and the United States.
On top of that, it's important to keep in mind that's just with melanoma. Verisante's technology has been proven to successfully identify many different types of cancers. Early trials have shown its effectiveness in identifying lung, cervical, and colon cancer.
Melanoma is just where Verisante's technology has had most of the research and testing geared towards. Once you add in potential opportunities in the other cancers, Verisante's potential is exponentially higher over the long run.
Nearing the Finish Line
Verisante seems to have it all. It's better, cheaper, and potentially very profitable. But the key with any investment in medical technology is completing the regulatory approval processes.
Verisante is aiming at completing the regularity approval process in a faster, less-costly way.
First, most of the expensive and time-consuming research is already completed. The Aura device has been in development for about 10 years. And it already has one six-year study completed.
Now Verisante is in the final stages of approval with Canadian medical authorities. Final approval is expected to be made by the end of 2011.
After that, Verisante has already started the European approval process. It expects to the "CE Mark" (the symbol of European approval) to be granted as early as the end of 2011.
If and when this is approved, Verisante has instant access to markets in the European Union, South Africa, and Australia.
Finally, with European and Canadian approval in hand, its' going to then move to the United States. It needs more studies for U.S. approval, but like many other drugs and medical devices, it's a lot more likely to get approval in the United States after Canada and Europe give the official thumbs up.
A Big Winner in the Making
Verisante Technology (TSX-V:VRS or OTCQX:VRSEF) is in position to have an exciting few months ahead as the story unfolds and even more great years beyond that.
It has all the elements of a giant med-tech success story.
It has superior, proven technology.
It has years of costly and time-consuming research behind it.
It's very near to final regulatory approval in Canada.
It has shown the potential to save a lot of lives too.
On top of all that, Verisante was recently able to attract an addition $5 million capital infusion in a market where med-tech and biotech aren't getting very much venture capital.
Perhaps most importantly, Verisante has huge growth potential. At a mere $35 market cap, the upside is tremendous. Remember, its closest competitor, MELAScience, had a market value of about $200 million just in anticipation it would be successful. And after it got rejected by the FDA, it still has a $90 million market value.
That's the kind of potential here where once the Aura is approved; Verisante is on its way to being worth $1 billion.
Head over to Verisante.com to see for yourself.
Andrew Mickey
Chief Investment Strategist, Q1 Publishing
Disclosure: The editor does not own shares and is not paid by any of the companies mentioned for distribution of this report. It is, however, an open recommendation in Q1 Publishing's President's List premium research service.
If you like ideas and research like this, the President's List is a premium investment research focused on the maximum risk-reward opportunities available anywhere in the world. You can learn more about a no-risk trial offer here. Legal Disclaimer : The information contained on this e-mail and in other Q1 Publishing communications is intended for general information purposes only. Q1 Publishing has not taken into account the specific investment objectives of any particular investor. You should always seek the counsel of a professional financial advisor before purchasing or selling stock. Directors, employees and outside contributors to Q1 Publishing may hold substantial positions in the recommended securities and may increase or decrease such positions without notice. We believe the sources of information to be reliable but Q1 Publishing does not guarantee the accuracy or completeness of the information provided on this website or in other Q1 communications, and expressly disclaims liability for any errors or omissions that may be contained in the information
Investorideas.com disclaimer and disclosure - the following news is a paid news release distribution (one thousand for 2 releases) Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
The published report by Q1 Publishing is the property of Q1 Publishing and is not the opinion of Investorideas.com
Investorideas.com invites investors trading gold and mining stocks to become a Facebook.com Fan and receive a free mining stocks directory
Investors can also Register for free online mining conference, Follow the Money in Mining and Metals
The stock directories are just one of the tools to help investors in the mining sector. This month, Investorideas.com and Smallcapvoice.com are hosting the online mining conference, Follow the Money in Mining and Metals, May 25th and 26. The online conference is free to investors with login registration.
Free Investor Sign-Up -http://www.smallcapvoice.com/ii_scv/investor-signup.html
Facebook Badge
Look for us on Facebook.com -
Investorideas.com- Investing ideas that can change the world
FACEBOOK BADGE
Investorideas.com- Investing ideas that can change the world
Promote Your Page TooAbout our mining stocks directory:
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory in PDF format lists over 1300 publicly traded mining companies. Mining and metals investors can research gold and mining stocks with the mining stocks directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks, Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges. directory features hyperlinks to stocks symbol(s), company’s URL and company’s description.
Email us at dawn@investorideas.com and let us know you have become a fan and we will email you the PDF free!
More mining stocks research - free online investor conference
Follow the Money in Mining and Metals, May 25th and 26.
The online conference is free to investors with login registration. The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST. It will be archived for three months and available with login. The conference pages will be featured for investors at both Investorideas.com and SmallCapvoice.com.
Resource speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
Learn More about the Mining Conference
http://www.investorideas.com/MSS/Conference.asp
Free Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up
http://www.smallcapvoice.com/ii_scv/company-signup.html
About our Mining Portals:
http://www.gold-miningstocks.com/ and http://www.miningsectorstocks.com/ are research portals within the InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory of over 1300 mining stocks.
Become an Investor Ideas Member
Investor Ideas members get access to the most comprehensive stock directories online with 24/7 login access to water stocks, renewable energy stocks and more. Learn more: http://www.investorideas.com/membership/
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Offer limited to first 25 new fans
Subscribe to:
Posts (Atom)